Impact of obesity on immune-related adverse events and tyrosine kinase inhibitor side effects in patients with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Alharbi, Malak
Tariq, Muhammad Junaid
Jatwani, Karan
George, Saby
机构：
[1] Roswell Pk Canc Inst, Buffalo, NY USA
[2] Roswell Pk Canc Inst, Buffalo, IL USA
[3] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4560
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A Tale of Immune-Related Adverse Events With Sequential Trials of Checkpoint Inhibitors in a Patient With Metastatic Renal Cell Carcinoma
    Singh, Vinit
    Chu, Yvonne
    Gupta, Varsha
    Zhao, Charlie Weige
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (06)
  • [22] A Potential Mechanism of Anticancer Immune Response Coincident With Immune-related Adverse Events in Patients With Renal Cell Carcinoma
    Kato, Taigo
    Tomiyama, Eisuke
    Koh, Yoko
    Matsushita, Makoto
    Hayashi, Yujiro
    Nakano, Kosuke
    Ishizuya, Yu
    Wang, Cong
    Hatano, Koji
    Kawashima, Atsunari
    Ujike, Takeshi
    Kawasaki, Keisuke
    Morii, Eiichi
    Gotoh, Kunihito
    Eguchi, Hidetoshi
    Kiyotani, Kazuma
    Fujita, Kazutoshi
    Nonomura, Norio
    Uemura, Motohide
    ANTICANCER RESEARCH, 2020, 40 (09) : 4875 - 4883
  • [23] Risk of hepatotoxicity with concurrent statin and tyrosine kinase inhibitor (TKI) or mTOR inhibitor (mTORi) in patients with metastatic renal cell carcinoma (mRCC).
    Au, Trang H.
    Bailey, Erin B.
    Patel, Shiven B.
    Tantravahi, Srinivas Kiran
    Agarwal, Neeraj
    Stenehjem, David D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [24] Effect of concomitant proton pump inhibitor (PPI) on effectiveness of tyrosine kinase inhibitor (TKI) in patients with metastatic renal cell carcinoma (mRCC).
    Au, Trang H.
    Bailey, Erin B.
    Patel, Shiven B.
    Tantravahi, Srinivas Kiran
    Agarwal, Neeraj
    Stenehjem, David D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [25] Correlation between immune-related adverse events and prognosis in renal cell carcinoma patients treated with nivolumab
    Kato, Taigo
    Nagahara, Akira
    Kawamura, Norihiko
    Nakata, Wataru
    Soda, Tetsuji
    Matsuzaki, Kyosuke
    Hatano, Koji
    Kawashima, Atsunari
    Ujike, Takeshi
    Imamura, Ryoichi
    Nishimura, Kensaku
    Takada, Shingo
    Tsujihata, Masao
    Yamaguchi, Seiji
    Takao, Tetsuya
    Nishimura, Kazuo
    Uemura, Motohide
    Nonomura, Norio
    ANNALS OF ONCOLOGY, 2021, 32 : S314 - S314
  • [26] The comparison of cytoreductive nephrectomy (CN) with tyrosine kinase inhibitor therapy alone in patients with primary metastatic renal cell carcinoma (mRCC).
    Hatakeyama, Shingo
    Naito, Sei
    Numakura, Kazuyuki
    Kato, Renpei
    Koguchi, Tomoyuki
    Kojima, Takahiro
    Kawasaki, Yoshihide
    Kandori, Kandori
    Tsushima, Eiki
    Nishiyama, Hiroyuki
    Ito, Akihiro
    Kojima, Yoshiyuki
    Habuchi, Tomonori
    Obara, Wataru
    Tsuchiya, Norihiko
    Ohyama, Chikara
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [27] Impact of steroid use among patients with renal cell carcinoma (RCC) who develop immune-related adverse events (irAE).
    Zang, Peter
    Resnick, Karen
    Larsen, Travis
    Ye, Shirley
    Choi, April
    Yu, Xiao
    Brady, Kevin
    Tulpule, Varsha
    D'souza, Anishka
    In, Gino Kim
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism
    Kobayashi, Mizuki
    Numakura, Kazuyuki
    Hatakeyama, Shingo
    Muto, Yumina
    Sekine, Yuya
    Sasagawa, Hajime
    Kashima, Soki
    Yamamoto, Ryohei
    Koizumi, Atsushi
    Nara, Taketoshi
    Saito, Mitsuru
    Narita, Shintaro
    Ohyama, Chikara
    Habuchi, Tomonori
    GENES, 2022, 13 (07)
  • [29] Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
    Hayase, T.
    Washino, S.
    Shirotake, S.
    Inoue, M.
    Kagawa, M.
    Takeshita, H.
    Miura, Y.
    Hyodo, Y.
    Izumi, K.
    Kawakami, S.
    Saito, K.
    Kageyama, Y.
    Oyama, M.
    Miyagawa, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S1488 - S1489
  • [30] Macrocytosis in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKI's)
    Khasawneh, M. F.
    Unnithan, J.
    Choueiri, T.
    Rini, B.
    Dreicer, R.
    Garcia, J.
    Wood, L.
    Elson, P.
    Bukowski, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345